Form 4: Sutro Biopharma CFO Edward Albini Reports Stock Transactions

CFO Edward Albini reports the vesting of restricted stock units and subsequent tax withholding by Sutro Biopharma.

Summary

• On March 1, 2024, Edward Albini, CFO and Secretary of Sutro Biopharma, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
• Albini vested 7,875 RSUs, which converted into common stock.
• The company withheld 3,227 shares of common stock at a price of $4.95 to cover income tax obligations related to the RSU vesting.
• Following these transactions, Albini directly owns 95,440 shares of Sutro Biopharma common stock and 23,625 RSUs.
• The RSUs vest in equal annual installments beginning March 1, 2024.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment.

Future Outlook

The remaining RSUs will continue to vest annually on March 1st, subject to continued service.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. This provides transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Companies like Amgen, Gilead, and Biogen are also subject to these regulations, and their executives file similar reports when conducting transactions in their company's stock.
• The reporting requirements are consistent across the industry, focusing on disclosing the nature, volume, and price of the transactions.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• Employees holding RSUs will experience similar vesting events.

Key Dates